Cargando…
Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era
The clinical outcome of patients with human epidermal growth factor receptor 2 (HER2) amplified breast carcinoma (BC) has improved with the development of anti-HER2 targeted therapies. However, patients can experience disease recurrence after curative intent and disease progression in the metastatic...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399304/ https://www.ncbi.nlm.nih.gov/pubmed/34454323 http://dx.doi.org/10.1016/j.breast.2021.08.007 |